Michael Asbach, DMSc, PA-C, Psych-CAQ

Panelists discuss how non-stimulant medication options with detailed clinical considerations.

Panelists discuss how comprehensive treatment approaches emphasize combination therapy and immediate implementation.

Panelists discuss how the critical role of pediatricians in ADHD diagnosis and treatment challenges.

Panelists discuss how ADHD risk factors include genetic, environmental, and socioeconomic influences.

Panelists discuss how ADHD diagnosis impacts families through stress and challenges but can also provide relief and understanding, while addressing quality of life effects including academic performance, family functioning, driving safety, and the need for structure and routine management.

Panelists discuss how diagnostic challenges include ensuring symptoms are developmentally appropriate, distinguishing ADHD from other conditions like depression and anxiety, and using tools like Vanderbilt and Connors scales to assess symptoms across multiple settings.

Diverse educational backgrounds bring complementary perspectives, strengths, and weaknesses that, when working together, can enhance the quality of care for patients and extend the reach of psychiatric services to underserved populations while maintaining quality and appropriate care.

Panelists discuss how the DSM-5-TR criteria for ADHD require at least 6 of 9 symptoms in either inattentive or hyperactive-impulsive domains, with inattentive presentations often going unrecognized especially in females and highly intelligent students.

Panelists discuss how ADHD presents in a 10-year-old boy with combined presentation symptoms, emphasizing the importance of seeing difficulties across multiple settings and noting the genetic component when family history is present.

Without the scaffolding of the REMS requirement for clozapine, how can you best utilize this treatment?

Check out these insights from clinicians at Real Psychiatry!

Let's explore COVID-19's impact on psychiatric research...

"Who are you important to? If you passed tomorrow, who would show up at your funeral?"

When prescribing ADHD medications, when is the best time to switch treatments?

Ancillary symptoms may be key in guiding treatment management for ADHD.

How can we get back to recovery as the treatment goal for schizophrenia?

2024 into 2025: a period of highs and lows for schizophrenia treatment.

A patient discusses their struggles coming to terms with a posttraumatic stress disorder (PTSD) diagnosis after multiple traumatic events, detailing their initial resistance to seeking help, the breakthrough moments in therapy that led to acceptance, and their ongoing journey of healing through various treatment approaches.

A panelist discusses how effective posttraumatic stress disorder (PTSD) management requires a comprehensive, individualized approach combining evidence-based treatments, ongoing support systems, lifestyle modifications, and regular monitoring of progress while acknowledging that recovery is often a gradual process requiring patience, persistence, and collaboration between health care providers and patients.

A panelist discusses how emerging posttraumatic stress disorder (PTSD) treatments, including psychedelic-assisted therapy, neurofeedback, transcranial magnetic stimulation, and virtual reality exposure protocols, show promising results in clinical trials while offering new hope for treatment-resistant cases.

A panelist discusses how clinicians implement posttraumatic stress disorder (PTSD) treatments through a carefully structured approach that begins with establishing safety and stabilization, progresses through trauma processing using evidence-based interventions, and concludes with integration and relapse prevention strategies, all while maintaining therapeutic alliance and adjusting treatment intensity based on patient response.

A panelist discusses how treatment options for posttraumatic stress disorder (PTSD) encompass a wide range of evidence-based approaches, including trauma-focused cognitive behavioral therapy, medication management, exposure therapy, and complementary interventions such as mindfulness and group support, which can be tailored to meet individual patient needs and circumstances.

A panelist discusses how a posttraumatic stress disorder (PTSD) diagnosis in clinical settings requires a comprehensive evaluation process that includes gathering detailed trauma history, assessing current symptoms through validated assessment tools, conducting differential diagnosis to rule out other conditions, and considering cultural and contextual factors that may influence symptom presentation.

A panelist discusses how clinicians employ a range of diagnostic tools for posttraumatic stress disorder (PTSD) assessment, including structured clinical interviews, standardized questionnaires such as the PCL-5, trauma screening instruments, and detailed behavioral observations to ensure accurate diagnosis and appropriate treatment planning.

An FDA committee recently decided the clozapine REMS protocol was no longer necessary. How will this impact clinicians?

A panelist discusses how diagnosing posttraumatic stress disorder (PTSD) presents unique challenges due to symptom overlap with other mental health conditions, varying presentation across different populations, and the often-delayed onset of symptoms following traumatic events.

A panelist discusses how posttraumatic stress disorder (PTSD) manifests through a complex web of symptoms, including intrusive memories, nightmares, hypervigilance, emotional numbness, and avoidance behaviors that significantly impact daily functioning and quality of life.

A panelist discusses how posttraumatic stress disorder (PTSD) alters key brain regions, such as the amygdala and hippocampus, with genetic predisposition, severity of trauma exposure, and lack of social support serving as critical risk factors that can influence both the likelihood of developing the condition and its neurobiological impact.

A panelist discusses how posttraumatic stress disorder (PTSD) permeates modern society at multiple levels, from individuals coping with personal trauma to collective trauma responses that shape community behaviors and social structures.

The authors of the Clinician's Corner column discuss the latest FDA-approved treatment for schizophrenia.